Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

578 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation.
Le Meur Y, Büchler M, Thierry A, Caillard S, Villemain F, Lavaud S, Etienne I, Westeel PF, Hurault de Ligny B, Rostaing L, Thervet E, Szelag JC, Rérolle JP, Rousseau A, Touchard G, Marquet P. Le Meur Y, et al. Among authors: marquet p. Am J Transplant. 2007 Nov;7(11):2496-503. doi: 10.1111/j.1600-6143.2007.01983.x. Epub 2007 Oct 1. Am J Transplant. 2007. PMID: 17908276 Free article. Clinical Trial.
Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses.
Kamar N, Marquet P, Gandia P, Muscari F, Lavayssière L, Esposito L, Guitard J, Canivet C, Peron JM, Alric L, Suc B, Saint-Marcoux F, Rostaing L. Kamar N, et al. Among authors: marquet p. Ther Drug Monit. 2009 Aug;31(4):451-6. doi: 10.1097/FTD.0b013e3181aa776e. Ther Drug Monit. 2009. PMID: 19531983
Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients.
Prémaud A, Rousseau A, Le Meur Y, Venisse N, Loichot C, Turcant A, Hoizey G, Compagnon P, Hary L, Debruyne D, Saivin S, Jacqz-Aigrain E, Marquet P. Prémaud A, et al. Among authors: marquet p. Pharmacol Res. 2010 Feb;61(2):167-74. doi: 10.1016/j.phrs.2009.09.006. Epub 2009 Oct 2. Pharmacol Res. 2010. PMID: 19800973
Cost-effectiveness analysis of individualized mycophenolate mofetil dosing in kidney transplant patients in the APOMYGRE trial.
Rousseau A, Laroche ML, Venisse N, Loichot-Roselmac C, Turcant A, Hoizey G, Compagnon P, Hary L, Debruyne D, Saivin S, Jacqz-Aigrain E, Buchler M, Villeneuve C, Vergnenègre A, Le Meur Y, Marquet P. Rousseau A, et al. Among authors: marquet p. Transplantation. 2010 May 27;89(10):1255-62. doi: 10.1097/TP.0b013e3181d75952. Transplantation. 2010. PMID: 20224514 Free article. Clinical Trial.
578 results